We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
251
Wealthspire Advisors (Maryland)
Maryland
$10K +$3.23K +155 +57%
FHB
252
First Hawaiian Bank
Hawaii
$8K -$979 -47 -13%
PFO
253
Pathstone Family Office
New Jersey
$8K – – –
BWA
254
BDO Wealth Advisors
Florida
$5K +$2.29K +110 +110%
Rockefeller Capital Management
255
Rockefeller Capital Management
New York
$5K +$4.39K +211 New
MNBTD
256
Moody National Bank Trust Division
Texas
$4K -$5.66K -272 -65%
WCM
257
WealthBridge Capital Management
Ohio
$4K -$1.23K -59 -26%
BCA
258
Berman Capital Advisors
Georgia
$4K – – –
RCAG
259
Rehmann Capital Advisory Group
Michigan
$3.61K – – –
CFGS
260
Concourse Financial Group Securities
Alabama
$3K +$271 +13 +11%
PCP
261
Proficio Capital Partners
Massachusetts
$3K +$2.31K +111 New
VFA
262
Valeo Financial Advisors
Indiana
$3K +$2.52K +121 New
LFA
263
Legacy Financial Advisors
Kentucky
$3K +$2.98K +143 New
ARMC
264
American Research & Management Company
Massachusetts
$2K – – –
Northwestern Mutual Wealth Management
265
Northwestern Mutual Wealth Management
Wisconsin
$2K +$208 +10 +11%
FHA
266
Flagship Harbor Advisors
Massachusetts
$1K – – –
TCOV
267
Trust Company of Vermont
Vermont
$1K +$895 +43 New
GT
268
Glenmede Trust
Pennsylvania
$197 -$86.5K -4,155 -34%
EC
269
EcoR1 Capital
California
– -$9.18M -644,002 Closed
KCM
270
Kingdon Capital Management
New York
– -$8.11M -569,298 Closed
PC
271
Polar Capital
United Kingdom
– -$5.7M -400,000 Closed
Alyeska Investment Group
272
Alyeska Investment Group
Illinois
– -$3.53M -248,000 Closed
SGA
273
Sector Gamma AS
Norway
– -$3.43M -240,522 Closed
SFM
274
Sphera Funds Management
Israel
– -$1.78M -125,000 Closed
ECM
275
ExodusPoint Capital Management
New York
– -$969K -68,002 Closed
8 9 10
11
12

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.